Prevalence and Molecular Study of Hepatitis C Virus with Evaluation of Response to Some Antiviral Treatments and Correlation with Cortisol Levels
The present investigation is an endevour to study the distribution of this virus depended on gender, age, source of infection, determine the genotype and viral load, as well as assess the response to antiviral treatments and its relationship to the level of cortisol. This research was conducted between January and March 2022 in the Gastroenterology and Hepatology facility in Baghdad. In the study, 90 people with HCV Antibody positivity (Ab+ve) took part. Each person had a full medical history, a clinical exam, and investigations. After doing the chi-square test, a statistically significant P value was determined to be <0.05. Peg interferon alpha 2a was administered once a week to each of these patients, along with ribavirin twice a day. They varied in age from 18 to 63, with a mean of 41.4 years, and 66 (73.3% of them) were male and 24 (26.7% of them) were female. The most common genotypes were 1:45 (50%) and 4:33 (36.7%). Only 27 patients (30%) have a viral load of more than 600,000Uml, while 63 patients (70%) have a viral load of less than 600,000Uml. End treatment virological response was seen in 34 individuals (37.7%). The results showed a significant increase in cortisol concentration for the patients group with a viral load > 600,000 iu/ml (267.89±16.60 ng/ml) compared with other groups, group viral load of <600,000 (126.84±4.55 ng/ml) and the control group (123.06±6.13 ng/ml).